Hottelart Carine, El Esper Najeh, Rose Françoise, Achard Jean-Michel, Fournier Albert
Department of Nephrology, CHU Amiens, France.
Nephron. 2002;92(3):536-41. doi: 10.1159/000064083.
Fenofibrate is a potent hypolipemic agent, widely used in patients with renal insufficiency in whom dyslipidemia is frequent. A moderate reversible increase in creatinine plasma levels is an established side effect of fenofibrate therapy, which mechanism remains unknown. We have previously reported that in 13 patients with normal renal function or moderate renal insufficiency, two weeks of fenofibrate therapy increased creatininemia without any changes in renal plasma flow and glomerular filtration rate [1]. In 13 additional patients, muscular enzymes (AST, GPT, CPK, LDH) and myoglobin were measured before and after 2 weeks on fenofibrate, and the values of creatininemia obtained by the Jaffé technique and HPLC were compared. CPK and AST activity and plasma myoglobin increased in 2 patients with fenofibrate, but muscular enzymes remained unchanged in the population as a whole, and were not correlated to the changes in creatininemia. The changes in creatininemia induced by fenofibrate measured by the Jaffé technique were strongly correlated to those measured by HPLC (r(2) = 0.675, p = 0.0006). Analysis of the pooled data of the two arms of the study showed in 26 patients that two weeks of fenofibrate therapy efficiently reduced total cholesterol and triglycerides plasma levels, and raised creatininemia from 139 +/- 8 to 160 +/- 10 micromol/l (p < 0.0001), but confirmed that creatininuria also increased to the extent that creatinine clearance remained unchanged (68 +/- 6 vs. 67 +/- 6 ml/min, n.s.). It is concluded that the increase in creatininemia induced by fenofibrate in renal patients does not reflect an impairment of renal function, nor an alteration of tubular creatinine secretion, and is not falsely increased by a dosage interference. Fenofibrate-induced increase of daily creatinine production is neither readily explained by accelerated muscular cell lysis. It is proposed that fenofibrate increases the metabolic production rate of creatinine.
非诺贝特是一种强效的降血脂药物,广泛应用于肾功能不全且血脂异常常见的患者。非诺贝特治疗的一个既定副作用是血浆肌酐水平出现中度可逆性升高,其机制尚不清楚。我们之前报道过,在13例肾功能正常或中度肾功能不全的患者中,两周的非诺贝特治疗使血肌酐升高,而肾血浆流量和肾小球滤过率无任何变化[1]。在另外13例患者中,在接受非诺贝特治疗2周前后测量了肌肉酶(AST、GPT、CPK、LDH)和肌红蛋白,并比较了用Jaffé技术和高效液相色谱法获得的血肌酐值。2例接受非诺贝特治疗的患者CPK和AST活性以及血浆肌红蛋白升高,但总体人群中肌肉酶保持不变,且与血肌酐变化无关。用Jaffé技术测得的非诺贝特诱导的血肌酐变化与高效液相色谱法测得的变化高度相关(r(2)=0.675,p=0.0006)。对该研究两组汇总数据的分析显示,在26例患者中,两周的非诺贝特治疗有效降低了血浆总胆固醇和甘油三酯水平,使血肌酐从139±8升高至160±10微摩尔/升(p<0.0001),但证实肌酐尿也增加到肌酐清除率保持不变的程度(68±6对67±6毫升/分钟,无显著性差异)。结论是,非诺贝特在肾病患者中诱导的血肌酐升高既不反映肾功能损害,也不反映肾小管肌酐分泌改变,且不受剂量干扰而假性升高。非诺贝特诱导的每日肌酐生成增加也不易用肌肉细胞加速裂解来解释。有人提出非诺贝特增加了肌酐的代谢生成率。